KRAS-mutated Metastatic Colorectal Cancer (mCRC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Colorectal cancer (CRC) is most frequently diagnosed in both sexes and is the second most common disease in both women and men. Because of their significant involvement in cancer, the RAS subfamily proteins KRAS, NRAS, and HRAS are some of the most thoroughly researched. The most prevalent RAS mutations are KRAS mutations (85%), followed by NRAS (15%) and HRAS (1%). In between 35 and 45 % of mCRC cases, KRAS mutations result in therapeutic resistance and a poor prognosis. There were more than 1.8 million new cases diagnosed in 2018. About 20% of newly diagnosed cases of colorectal cancer already have metastatic disease, and another 20% of cases progress to metastatic colorectal cancer (mCRC), which has a much lower survival rate. In the past ten years, there has been a decline in the number of new cases of CRC, especially in Western nations. This has happened for a number of reasons, including the use of colonoscopies as screening tests, the use of chemo preventive medications like non-steroidal anti-inflammatory drugs (NSAIDs), and the association of healthy diets, nutritional supplements, and regular exercise.

Description

Colorectal cancer (CRC) is most frequently diagnosed in both sexes and is the second most common disease in both women and men. Because of their significant involvement in cancer, the RAS subfamily proteins KRAS, NRAS, and HRAS are some of the most thoroughly researched. The most prevalent RAS mutations are KRAS mutations (85%), followed by NRAS (15%) and HRAS (1%). At the time of diagnosis, about 20% of newly diagnosed cases of colorectal cancer are metastatic, and another 20% of cases progress to metastatic colorectal cancer (mCRC), which has a much lower survival rate. The implementation of routine KRAS- and BRAF-mutation testing over the past 20 years has completely changed how mCRC is molecularly characterized. The prognosis is reportedly very bad for people who have BRAF and KRAS mutations. Despite extensive concerted efforts over the past thirty years, developing drugs that specifically target KRAS, the most frequently mutated oncogene in cancer, has not been successful. Given the significant role that this driver oncogene plays, KRAS drugging continues to be a difficult problem for cancer research.

KRAS-mutated Metastatic Colorectal Cancer (mCRC) (Epidemiology)

In between 35 and 45 % of mCRC cases, KRAS mutations result in therapeutic resistance and a poor prognosis. There were more than 1.8 million new cases diagnosed in 2018. About 20% of newly diagnosed cases of colorectal cancer already have metastatic disease, and another 20% of cases progress to metastatic colorectal cancer (mCRC), which has a much lower survival rate. KRAS mutations, which are present in 35-45% of mCRC, are associated with a poor prognosis and therapeutic resistance. KRAS is regarded as an "undruggable" oncoprotein that is resistant to medication. KRAS G12C, one of the most prevalent KRAS mutants in cancer, is present in 10%-20% of all KRAS G12 mutations.

KRAS-mutated Metastatic Colorectal Cancer (mCRC) -Current Market Size & Forecast Trends

The market for KRAS-mutated metastatic colorectal cancer (mCRC) is expected to experience substantial growth, driven by the increasing prevalence of KRAS mutations in colorectal cancer, which affects approximately 40% of mCRC patients. The global market for mCRC therapies is projected to reach around USD 19.90 billion by 2033, with a significant portion attributed to targeted therapies aimed at KRAS mutations, particularly the G12C variant. Recent advancements, such as the FDA's accelerated approval of adagrasib in combination with cetuximab for KRAS G12C-mutated mCRC, highlight the growing focus on personalized treatment options. With ongoing clinical trials and the development of new therapies targeting various KRAS mutations, the market is well-positioned for robust growth through 2035, as these innovations promise to improve patient outcomes and address unmet medical needs in this challenging cancer type.

In the past ten years, there has been a decline in the number of new cases of CRC, especially in Western nations. This has happened for a number of reasons, including the use of colonoscopies as screening tests, the use of chemo preventive medications like non-steroidal anti-inflammatory drugs (NSAIDs), and the association of healthy diets, nutritional supplements, and regular exercise. The outcome of CRC patients has also significantly improved, especially for those with metastatic CRC (mCRC), as the median overall survival has more than doubled in the last 20 years, reaching about 30 months. This amelioration in the treatment of mCRC has been obtained by combining different cytotoxic drugs, in particular the protracted infusion of 5-fluorouracil modulated by leucovorin in combination with irinotecan (FOLFIRI) or with oxaliplatin (FOLFOX), capecitabine and oxaliplatin combination (XELOX) or 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) and subsequently, by the introduction of targeted-therapy.

Report Highlights

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - Current Market Trends

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - Current & Forecasted Cases across the G8 Countries

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - Market Opportunities and Sales Potential for Agents

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - Patient-based Market Forecast to 2035

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - Untapped Business Opportunities

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - Product Positioning Vis-a-vis Competitors' Products

KRAS-mutated Metastatic Colorectal Cancer (mCRC) - KOLs Insight